- Home
- MFM vs ACHV Comparison
MFM vs ACHV Comparison
Compare MFM & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFM | ACHV |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.2M | 231.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MFM | ACHV |
|---|---|---|
| Price | $5.55 | $4.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 108.1K | ★ 759.3K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $176.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.37 | $1.84 |
| 52 Week High | $5.48 | $6.03 |
Technical Indicators
Market Signals| Indicator | MFM | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 58.71 | 40.91 |
| Support Level | $5.51 | $4.00 |
| Resistance Level | $5.58 | $4.47 |
| Average True Range (ATR) | 0.06 | 0.29 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 69.57 | 26.69 |
Price Performance
Historical ComparisonAbout MFM MFS Municipal Income Trust
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.